INSMED INC Income (Loss) from Continuing Operations before Income Taxes, Domestic
INSMED INC (INSM) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$1.12 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-19
- INSMED INC income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$1.12B.
- INSMED INC income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$814.53M.
- INSMED INC income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$666.18M.
- INSMED INC income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$406.26M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$1.12B 10-K · filed 2026-02-19 |
| 2024-12-31 | -$814.53M 10-K · filed 2026-02-19 |
| 2023-12-31 | -$666.18M 10-K · filed 2026-02-19 |
| 2022-12-31 | -$406.26M 10-K · filed 2025-02-20 |
| 2021-12-31 | -$348.85M 10-K · filed 2024-02-22 |
| 2020-12-31 | -$207.12M 10-K · filed 2023-02-23 |
| 2019-12-31 | -$201.16M 10-K · filed 2022-02-17 |
| 2018-12-31 | -$286.21M 10-K · filed 2021-02-25 |
| 2017-12-31 | -$136.68M 10-K · filed 2020-02-25 |
| 2016-12-31 | -$140.35M 10-K · filed 2019-02-22 |
| 2015-12-31 | -$100.28M 10-K · filed 2018-02-23 |
| 2014-12-31 | -$89.58M 10-K · filed 2017-02-23 |
| 2013-12-31 | -$57.29M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |